---
title: "Ping An Securities: Maintains \"Strong Buy\" rating on YUYUE MEDICAL, optimistic about the company's sustained growth capability"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/254403170.md"
description: "Ping An Securities maintains a \"Strong Buy\" rating on YUYUE MEDICAL, believing that the company has strong sustainable growth capabilities. In the first half of 2025, YUYUE MEDICAL achieved a net profit attributable to the parent company of 1.203 billion yuan, a year-on-year increase of 7.37%; in the second quarter, the net profit attributable to the parent company was 578 million yuan, a year-on-year increase of 25.43%. The company has performed outstandingly in businesses such as blood glucose AED, and its overseas operations are steadily advancing, becoming an important driver of performance growth. YUYUE MEDICAL is building a health management ecosystem of \"hardware + software + data\" and has launched the YUYUE AIAgent application to enhance user stickiness"
datetime: "2025-08-25T09:19:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/254403170.md)
  - [en](https://longbridge.com/en/news/254403170.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/254403170.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/254403170.md) | [English](https://longbridge.com/en/news/254403170.md)


# Ping An Securities: Maintains "Strong Buy" rating on YUYUE MEDICAL, optimistic about the company's sustained growth capability

Ping An Securities' research report pointed out that YUYUE MEDICAL achieved a net profit attributable to the parent company of 1.203 billion yuan in the first half of 2025, a year-on-year increase of 7.37%. In the second quarter alone, the company achieved a net profit attributable to the parent company of 578 million yuan, a year-on-year increase of 25.43%. The performance growth is in line with expectations, with outstanding performance in blood glucose AED and other businesses; overseas business is steadily advancing, becoming an important driver of performance growth. The company is gradually building an integrated health management ecosystem of "hardware + software + data," launching the YUYUE AIAgent application in the first half of 2025, providing an important interface to enhance user stickiness. The company is a leading enterprise in the domestic medical device industry, with significant product and quality advantages. The "YUYUE" brand is deeply rooted in people's hearts, with the scale of various product businesses continuously expanding, product categories constantly being developed, and the company's overall competitive ability and risk resistance significantly improving. Considering the company's continuously growing comprehensive strength, the continuous release of new products, and the rapid development of overseas business, we are optimistic about the company's sustained growth capability and maintain a "strong buy" rating

### 相關股票

- [YUYUE MEDICAL (002223.CN)](https://longbridge.com/zh-HK/quote/002223.CN.md)

## 相關資訊與研究

- [BREAKINGVIEWS-Donald Trump’s biggest trade shock is yet to come: podcast](https://longbridge.com/zh-HK/news/278498422.md)
- [Tennis-Gauff retires from Indian Wells match due to elbow pain](https://longbridge.com/zh-HK/news/278312995.md)
- [Air India to operate special flights for UAE on March 8 amid Gulf crisis](https://longbridge.com/zh-HK/news/278239013.md)
- [Pickled cucumber item Uncle Yiannis’ Baby Gherkins recalled after undeclared allergen detected: SFA](https://longbridge.com/zh-HK/news/278746011.md)
- [13:16 ETAJPC Publishes POLY-ACS Trial Demonstrating Feasibility of Polypill Strategy After Acute Coronary Syndrome](https://longbridge.com/zh-HK/news/278594471.md)